Vericel Business Summary

Vericel Corporation (VCEL) is a commercial-stage biopharmaceutical leader specializing in advanced autologous cell-based therapies for the sports medicine and severe burn care markets. The company generates revenue primarily through the sale of its three core proprietary products: MACI (autologous cultured chondrocytes on a porcine collagen membrane) for knee cartilage repair, Epicel (cultured epidermal autografts) for permanent skin replacement in patients with deep-thickness burns, and NexoBrid, an enzymatic debridement agent licensed from MediWound for severe thermal burns. Vericel operates through two primary business segments: Sports Medicine, which accounts for approximately 87% of total revenue, and Burn Care. As of early 2026, the company maintains a dominant market position with preliminary 2025 revenues of $276 million and a robust 74% gross margin. Its primary direct competitors include Organogenesis Holdings, Smith & Nephew (following its acquisition of CartiHeal), Zimmer Biomet, and B. Braun; Vericel distinguishes itself as a market leader by offering the first FDA-approved tissue-engineered autologous cellularized scaffold for cartilage repair. Vericel’s leadership is anchored by President and CEO Dominick (Nick) Colangelo, who has led the company since 2013 and spearheaded its 2014 transformation from Aastrom Biosciences through the strategic acquisition of Sanofi’s cell therapy assets. Colangelo brings over 20 years of biopharmaceutical experience, including a decade-long tenure at Eli Lilly and Company. The executive team includes Chief Financial Officer Joe Mara, a biotech finance veteran who joined in 2021, and Chief Operating Officer Michael Halpin, who oversees the company’s specialized manufacturing and regulatory operations. The Board of Directors is chaired by Dr. Robert L. Zerbe, a former senior executive at Eli Lilly and Pfizer, and includes notable industry figures such as Alan Rubino and Heidi Hagen, who provide deep expertise in drug delivery and cell therapy commercialization. The company is backed by significant institutional investors, including BlackRock and The Vanguard Group, reflecting strong market confidence in its specialized regenerative medicine platform.